How Nurses Can Support Physicians in Identifying Colorectal Cancer Risk

Video

Ascertaining family history and promoting screening are key.

Nurses can support providers in identifying patients’ colorectal cancer risk by enabling them with the tools and information needed to assess it.

“Colorectal cancer is the most preventable solid tumor on the planet,” says Thomas Weber, MD, FACS, founder and president of the Colon Cancer Foundation.

In this video, Weber explains how nurses can focus on ascertaining patients’ family history and ensuring that patients get their colonoscopies when they are due.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Image of a woman with gray hair on a light blue background
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a private infusion bay with a large screen for video calls
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a man wearing scrubs in front of a blue background
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with blonde hair wearing a denim jacket in front of a blue background
Related Content
Graphic reading "FDA APPROVED" resembling a seal of approval

Retifanlimab Receives FDA Approval for Advanced Anal Cancer

Bridget Hoyt
May 15th 2025
Article

Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.

The Vitals

ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

Lindsay Fischer
October 31st 2023
Podcast

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Graphic reading "FDA APPROVED" resembling a stamp of approval

Cabozantinib Approved for Unresectable, Advanced/Metastatic epNET and pNET

Bridget Hoyt
March 26th 2025
Article

The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.

The Vitals

Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

Lindsay Fischer
March 1st 2023
Podcast

In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.

Anatomical diagram of a person with the gastrointestinal tract highlighted in orange

OS Benefit With T-DXd in Unresectable/Metastatic HER2+ Gastric/GEJ Adenocarcinoma

Chris Ryan
March 6th 2025
Article

T-DXd delivered an OS benefit for patients with unresectable or metastatic HER2-positive gastric and GEJ adenocarcinoma following trastuzumab-based treatment.

green background with dark blue text indicating FDA and green text indicating approved with a checkmark

FDA Approves Tislelizumab Combo for Advanced ESCC

Ashling Wahner;Kristi Rosa
March 4th 2025
Article

The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with PD-L1-positive, unresectable or metastatic esophageal squamous cell carcinoma.